Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fanregratinib in advanced solid malignancies
NCT03160833Phase 2Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fanregratinib in solid tumor, sponsored by Hutchison MediPharma (HMP). Status: unknown.
02
Drugs
fanregratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03160833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160833.